

## Vitamin K

<https://open-global.kcl.ac.uk/vitamin-k/>



**Date of preparation:** January 2019

**Contribution:** Jessica Farebrother, Kerry Jones

Dr Jessica Farebrother Dr. sc. ETH Zurich, OpeN-Global Team

*With:*

Dr Kerry Jones PhD, OpeN-Global Expert Partner

NIHR BRC Nutritional Biomarker Laboratory, University of Cambridge, Cambridge UK

Website: <http://www.mrc-epid.cam.ac.uk>

**Keywords:** clotting, pro-coagulant, osteoporosis, calcification, inflammation, oxidative stress, apoptosis

### Importance of vitamin K for health

Vitamin K is essential for normal blood coagulation; it functions as a co-enzyme during the synthesis of several proteins involved in coagulation. Importantly, these proteins include prothrombin (also known as coagulation Factor II). In individuals with vitamin K deficiency, the “prothrombin time” increases, and in severe cases can lead to haemorrhage (1). Vitamin K is also important in bone metabolism.

Vitamin K occurs in several different forms, but all share the menadione ring structure (2-naphthoquinone). Phylloquinone (2-methyl-3-phytyl-1,4-naphthoquinone), known as vitamin K<sub>1</sub>, is found in all green vegetables such as spinach, broccoli, kale and Swiss Chard, which contain >200 µg/100 g (2, 3). Bioavailability in green vegetables is low (<10%). Some fat consumed concomitantly helps the absorption of the vitamin in the digestive tract. Soybean and canola oil are also sources of vitamin K (100 µg/ 100 g) with a higher bioavailability (2), though these oils are likely consumed in lesser quantities than green leafy vegetables, bringing the overall contribution relatively similar.

#### Vitamin K

Jessica Farebrother & Kerry Jones

*Date of preparation:* December 2018

<https://open-global.kcl.ac.uk/vitamin-k/>

OpeN-Global

[www.open-global.kcl.ac.uk](http://www.open-global.kcl.ac.uk)

King's College London, UK

The second form of vitamin K, the menaquinones, collectively known as vitamin K<sub>2</sub>, have a long chain with 6 to 13 isoprenoid units in the 3-position, and are denoted by MK-*n*, where *n* signifies the number of isoprenoid units (4-6). Menaquinones are produced by bacterial fermentation, either in the large intestine (mainly by *Bacteriodes spp.*), or in foods such as cheese, curd and natto, a Japanese food made of fermented soya beans (3-6). Menaquinones have a different bioavailability – almost 100% from dairy produce (6, 7). They also have different pharmacokinetics to phylloquinones, leading to variable plasma half-life times (4) and distribution. Menaquinones produced by intestinal bacterial are, however, poorly available for intestinal absorption (8). The composition of menaquinone intake varies regionally, depending on the type of produce being consumed in the habitual diet (9) and may be a relatively small contributor to total vitamin K intake.

MK-4 is different to other menaquinones, in that it is not a major bacterial product, but is formed by the cellular alkylation of Vitamin K<sub>3</sub> (menadione; 2-methoyl-1,4-naphthoquinine), which is a synthetic form of vitamin K found in animal feed and thus originates from animal products, or from phylloquinone, with menadione as intermediate (4).

#### *Risk and consequences of vitamin K deficiency*

Due to dietary ubiquity and recycling of the vitamin K molecule, vitamin K deficiency is rare in adults, and mainly limited to those with disorders of fat absorption and digestion (2). However, low vitamin K intakes are associated with an increased risk of osteoporotic fractures (2) and are associated with a higher risk of cardiovascular disease, though data from clinical trials on the beneficial role of vitamin K do not support supplementation (3).

Vitamin K deficiency is much more frequent in neonates than in adults, since infants are born vitamin K-deficient due to poor maternal-placental transfer (2), and a low endogenous production due to a sterile gut (8).

**WHO recommendation (2018):** *All newborns should be given 1 mg of vitamin K intramuscularly after birth [after the first hour during which the infant should be in skin-to-skin contact with the mother and breastfeeding should be initiated]. (Strong recommendation, moderate quality evidence.) See <https://extranet.who.int/rhl/topics/newborn-health/care-newborn-infant/who-recommendation-haemorrhagic-disease-prophylaxis-using-vitamin-k>*

#### *Risks of vitamin K excess*

Vitamin K is not toxic, and there is no upper limit within current dietary reference intakes (2).

## Human biomarkers of population vitamin K status

To date, population surveys including assessment of vitamin K intake have relied on dietary intake and food frequency questionnaires, however the data generated are inconsistent (9).

Biomarkers of vitamin K status have been reviewed in (3). There is currently no single biomarker of vitamin K status for use in population studies (3, 9), and data are complex to interpret (3). Of the available biomarkers of vitamin K activity, whilst they respond to phylloquinone repletion following a period of depletion there are none for which a dose-response relationship with phylloquinone intake has been firmly established (3).

*Circulating vitamin K* can be measured in serum/plasma as phylloquinone, and most available data are related to phylloquinone (3).

*Phylloquinone* is readily detected in the circulation, and levels respond to intake, however the relatively short half-life (10) means that circulating concentrations reflect recent intake only (9), and no cut-off values to determine adequate vitamin K status are, to date, available (3).

Because of their strong association consideration should be given to the adjustment of plasma phylloquinone concentration relative to triacylglyceride concentration (3).

Methods: **HPLC with fluorescence detection and LC-mass spectrometry**, on fasting blood samples. See SOP available on page 3 of [www.open-global.kcl.ac.uk/vitamin-k/](http://www.open-global.kcl.ac.uk/vitamin-k/)

**Sample type:** Phylloquinone may be measured in plasma or serum.

**Quality control:** Analytical procedures should be performed under subdued lighting and samples stored at <20°C.

*Other methods:*

*The menaquinones* can be measured by HPLC but circulating concentrations are generally much lower than phylloquinone except in specific population groups or in people taking menaquinone-containing supplements and thus have not been adopted for population assessment (9).

*Undercarboxylated vitamin K-dependent proteins* can be measured to assess vitamin K status. When vitamin K is insufficient, the post-translational carboxylation of vitamin K-dependent proteins, such as prothrombin, is reduced. The undercarboxylated (inactive) fraction rises and can be detected.

*Undercarboxylated prothrombin*, PIVKA-II, is measurable in circulation, however is not used as a population biomarker as the commercially-available kits have a low sensitivity in detecting variation, except in individuals with chronic kidney disease (9). It is most often used in clinical settings.

*Osteocalcin:* An alternative is to measure osteocalcin, a vitamin K dependent protein synthesised uniquely during bone formation. Osteocalcin is detectable in serum, and the undercarboxylated

portion of the protein is responsive to changes in vitamin K intake (9). It is thought to be a more sensitive indicator for individuals in the community than PIVKA-II (9). Osteocalcin is measured by immunoassay or mass spectrometry (9).

*Urinary biomarkers* of vitamin K status are available, which measure urinary  $\gamma$ -carboxyglutamic acid (Gla) and menadione, but these are yet restricted to a clinic setting, since 24h urine collection is required (9).

*Prothrombin time* is the only vitamin K biomarker for which a change (increase) has been associated with vitamin K deficiency (3). It is used in a clinical setting.

### **Accreditation schemes**

KEQAS: Vitamin K External Quality Assurance Scheme

<https://www.guysandstthomas.nhs.uk/our-services/human-nutristasis/vitkegas.aspx>

This scheme assures the quality of laboratory measurements of phylloquinone, Vitamin K<sub>1</sub>, with the intention of harmonisation of methods for vitamin K analysis and their application to nutritional and clinical studies.

Participating laboratories receive four batches of three samples annually and are required to analyse them during specific periods over the course of the year. When results are returned, they are subjected to statistical analysis including an outliers test and a Z scoring system. Members then receive comprehensive reports detailing their performance.

KEQAS is a UKNEQAS affiliated EQA scheme. Viapath Analytics LLP, operating KEQAS, is a UKAS accredited proficiency testing provider (No. 7586).

Laboratories interested in participating in the KEQAS scheme should contact David Card ([david.card@viapath.co.uk](mailto:david.card@viapath.co.uk))

Join the KEQAS LinkedIn group: <https://www.linkedin.com/groups/2675928/about>

KEQAS provide technical advice for users of the supported laboratory methods. Contact [david.card@viapath.co.uk](mailto:david.card@viapath.co.uk)

For further information, contact the OpeN-Global team via [www.open-global.kcl.ac.uk/contact/](http://www.open-global.kcl.ac.uk/contact/)

### **Useful links**

European Food Safety Authority (EFSA) Dietary reference values for vitamin K:

<https://www.efsa.europa.eu/en/efsajournal/pub/4780>

NIH Factsheet for Health Professionals: Vitamin K <https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/>

### Further reading

Booth SL, Rajabi AA 2008 Determinants of Vitamin K Status in Humans Vitamin K. Vol., 1-22.

Card DJ, Gorska R, Cutler J, Harrington DJ 2014 Vitamin K metabolism: current knowledge and future research. Mol Nutr Food Res 58:1590-1600.

Santorino D, Siedner MJ, Mwanga-Amumpaire J, Shearer MJ, Harrington DJ, Wariyar U 2015 Prevalence and Predictors of Functional Vitamin K Insufficiency in Mothers and Newborns in Uganda. Nutrients 7:8545-8552.

Shearer MJ, Fu X, Booth SL 2012 Vitamin K nutrition, metabolism, and requirements: current concepts and future research. Adv Nutr 3:182-195.

Theuwissen E, Magdeleyns EJ, Braam LA, Teunissen KJ, Knapen MH, Binnekamp IA, van Summeren MJ, Vermeer C 2014 Vitamin K status in healthy volunteers. Food Funct 5:229-234.

Tie JK, Stafford DW 2016 Structural and functional insights into enzymes of the vitamin K cycle. J Thromb Haemost 14:236-247.

Tsugawa N 2015 Cardiovascular Diseases and Fat Soluble Vitamins: Vitamin D and Vitamin K. Journal of nutritional science and vitaminology 61 Suppl:S170-172

### References

1. Institute of Medicine (US) Panel on Micronutrients 2001 Chapter 5, Vitamin K, Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc.,. Vol. National Academies Press (US). Copyright 2001 by the National Academy of Sciences. All rights reserved., Washington (DC).
2. Suttie JW, Booth SL 2011 Vitamin K. Adv Nutr 2:440-441.
3. EFSA Panel on Dietetic Products NA 2017 Dietary reference values for vitamin K. EFSA Journal 15:e04780.
4. Beulens JW, Booth SL, van den Heuvel EG, Stoecklin E, Baka A, Vermeer C 2013 The role of menaquinones (vitamin K(2)) in human health. Br J Nutr 110:1357-1368.
5. Fu X, Harshman SG, Shen X, Haytowitz DB, Karl JP, Wolfe BE, Booth SL 2017 Multiple Vitamin K Forms Exist in Dairy Foods. Current Developments in Nutrition 1:e000638-e000638.

6. Vermeer C, Raes J, van 't Hoofd C, Knapen MHJ, Xanthoulea S 2018 Menaquinone Content of Cheese. *Nutrients* **10**.
7. Gijbbers BL, Jie KS, Vermeer C 1996 Effect of food composition on vitamin K absorption in human volunteers. *Br J Nutr* **76**:223-229.
8. Lippi G, Franchini M 2011 Vitamin K in neonates: facts and myths. *Blood Transfus* **9**:4-9.
9. Shea MK, Booth SL 2016 Concepts and Controversies in Evaluating Vitamin K Status in Population-Based Studies. *Nutrients* **8**.
10. Jones KS, Bluck LJ, Wang LY, Coward WA 2008 A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption. *European journal of clinical nutrition* **62**:1273-1281.